Skip to main content

Enrollment in the Health Benefits for Immigrant Adults (HBIA) program will be temporarily paused effective July 1, 2023.

Enrollment in the Health Benefits for Immigrant Seniors (HBIS) program will be temporarily paused effective Nov. 6, 2023.

Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: June 17, 2009

Drug Name Review Type Class Manufacturer
Texacort New Drug Initial Review Topical Corticosteroid JSJ
CNL8 Nail Kit New Drug Initial Review Topical Antifungal JSJ
Flector Patch New Drug Initial Review Topical NSAID King
Kapidex New Drug Initial Review Proton Pump Inhibitor Takeda
Cinryze New Drug Initial Review Hereditary Angioedema ViroPharm
Banzel New Drug Initial Review Anticonvulsant Eisai
Vimpat New Drug Initial Review Anticonvulsant UCB
Durezol New Drug Initial Review Ophthalmic- Anti-Inflammatory Sirion
Aplenzin New Drug Initial Review Antidepressants - Other Sanofi
Simponi New Drug Initial Review Biologic Modifier Centocor
Zanaflex Caps New Drug Initial Review Skeletal Muscle Relaxant Acorda
Rapaflo New Drug Initial Review BPH Agent Watson
Gelnique Gel New Drug Initial Review Urinary Anti-Incontinence Agent Watson
Equetro New Drug Appeal Bipolar I Disorder Validus
Zemplar New Drug Appeal Hyperparathyroidism due to CKD Abbott
Trilipix New Drug Appeal Lipotropics - Other Abbott
Simcor New Drug Appeal Lipotropics- Statins & Combinations Abbott
Vigamox PDL Appeal Ophthalmic - Antibiotics Alcon